Q-omics provides the consensus-scored FABP5P14 profile across patient tissues and cancer cell-line models. FABP5P14 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FABP5P14 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FABP5P14 RNA expression shows 7,398 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KIRC, and SARC as cancer lineages where FABP5P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FABP5P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FABP5P14 survival associations across molecular data types. FABP5P14 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FABP5P14 RNA expression–survival associations across cancer types. High FABP5P14 expression shows unfavorable associations in KIRC, COAD, STAD and DLBC, but favorable associations in HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FABP5P14 RNA expression.
This table summarizes FABP5P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FABP5P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FABP5P14 shows lower tumor expression in KIRC, THCA, LUSC, BLCA, HNSC and COAD. The KIRC box plot shows higher FABP5P14 RNA expression in normal versus tumor tissue (log2 FC = −0.076, t-test p < 0.001).
This table shows molecular features associated with FABP5P14 in patient tissues and cancer cell lines. In patient samples, FABP5P14 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
